2/2 APOL1 Long-Term Kidney Transplantation Outcomes Network- Clinical Center

项目摘要（摘要） 哥伦比亚-宾夕法尼亚临床联盟（CPCC）汇集了经验丰富的多学科团队， 哥伦比亚大学医学中心和宾夕法尼亚大学的临床和基础科学家研究人员 移植计划。CPCC调查人员在移植流行病学领域具有专业知识， 免疫学，遗传学和伦理学，以及与联合国网络的广泛合作历史， 器官共享（UNOS）和其他CPCC成员移植计划。因此，CPCC非常适合于 招募并保留患者进行APOL 1长期肾移植结局的纵向随访 研究网络（APOLLO）。该拟议的临床中心将包括26个儿科和成人大型， 中小型移植中心和9个器官采购组织，主要分布在4个 美国东北部的相邻州（纽约、新泽西、康涅狄格和宾夕法尼亚）。我们的主要目标是招募所有 非洲血统（如非洲裔美国人和西班牙裔黑人）及其在财团内的接受者， APOLLO网络的遗传和基因组研究（目标1）。我们将跟踪所有招募的捐赠者和接受者 纵向收集生物样本和临床结果，沿着与器官的务实整合 采购和移植网络（OPTN）、UNOS和美国肾脏数据系统 （USRDS）数据（目标2）。我们在多中心招募和保留少数患者方面的经验 研究，以及使用与UNOS，USRDS和其他地理空间数据相关联的创新分析，将 对阿波罗网络有利。我们希望我们独特的设计和实施专业知识， APOLLO研究将解决两种APOL 1风险变异的存在与以下假设相关的假设： 肾移植后较差的同种异体移植物结局， 受影响的活体捐赠者

Project Summary (Abstract) The Columbia-Penn Clinical Consortium (CPCC) brings together an experienced multidisciplinary team of clinical and basic scientist investigators at Columbia University Medical Center and University of Pennsylvania Transplant Programs. The CPCC investigators have expertise in the fields of transplant epidemiology, immunology, genetics and ethics, as well as an extensive history of collaboration with the United Network for Organ Sharing (UNOS) and other CPCC member transplant programs. As a result, the CPCC is well suited to recruit and retain patients for longitudinal follow up for the APOL1 Long-term Kidney Transplantation Outcomes Research Network (APOLLO). This proposed Clinical Center will comprise of 26 pediatric and adult large, medium and small size transplant centers and 9 organ procurement organizations predominantly in four contiguous states (NY, NJ, CT and PA) in the northeast US. Our primary objective is to enroll all donors of African ancestry (e.g. African-Americans and Black Hispanic) and their recipients within the consortium for genetic and genomic studies by the APOLLO Network (Aim 1). We will follow all recruited donor-recipient pairs with longitudinal collection of biospecimens and clinical outcomes along with pragmatic integration with Organ Procurement and Transplantation Network (OPTN), UNOS and the United States Renal Data System (USRDS) data (Aim 2). Our experience in the recruitment and retention of minority patients in multicenter studies, as well as the use of innovative analytics with linkage to UNOS, USRDS and other geospatial data, will be of benefit to the APOLLO Network. We expect that our unique design and implementation expertise to the APOLLO study will address the hypothesis that the presence of two APOL1 risk variants is associated with inferior allograft outcomes following kidney transplant and increases the risk of adverse renal outcomes for affected living donors.